The abstract is read at the publisher; the summary is JClub's.
Birth after July 1986 in the universal neonatal HBV vaccination era is linked to higher HBsAg seroclearance in 415 HIV-1/HBV coinfected people on tenofovir ART.
- Why it matters: Long-term tenofovir ART’s effect on HBsAg loss is unclear in HBV-hyperendemic settings with universal neonatal vaccination, where baseline infection patterns differ.
- What they did: HBsAg-positive participants receiving tenofovir-containing ART from 2011–2023 were followed for a median 9.4 years; Cox models tested predictors of seroclearance using baseline markers and outcomes through December 2025.
- The result: Only 35/415 (8.4%) achieved seroclearance over 3600 person-years (0.97 per 100 person-years), and seroclearance was associated with no seroreversion, cirrhosis, or HCC.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.